Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: Report of a case

Hajjar, Leila R.; Kim, WooShin; Nolan, George H.; Turner, Sharon L; Raju, Usha R.

doi:10.1016/0020-7292(94)90266-6

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, endometriosis is rare in postmenopausal women and the finding of endometriosis in tamoxifen-treated postmenopausal women raises the possibility of a link between tamoxifen use and endometriosis. This possibility is further supported by the unusual morphological features and behavior of endometriosis in tamoxifen treated postmenopausal women (Hajjar et al 1993;Cohen et al 1994a;Ismail and Maulik, 1997). One patient had pelvic endometriosis infi ltrating the cervix, vagina, rectum, and sigmoid colon (Hajjar et al 1993).…”

Section: Endometriosismentioning

confidence: 89%

“…This possibility is further supported by the unusual morphological features and behavior of endometriosis in tamoxifen treated postmenopausal women (Hajjar et al 1993;Cohen et al 1994a;Ismail and Maulik, 1997). One patient had pelvic endometriosis infi ltrating the cervix, vagina, rectum, and sigmoid colon (Hajjar et al 1993). Another patient had a cystic ovarian endometriotic cyst with apparent infiltration of adjacent structures (Ismail and Maulik, 1997).…”

Section: Endometriosismentioning

confidence: 94%

“…The development of endometriosis has been reported in women receiving tamoxifen for the treatment of breast cancer ( Ford et al 1988 ; Cano et al 1989 ; Hajjar et al 1993 ; Cohen et al 1994b ; Morgan et al 1994 ). A histopathologic analysis of endometriosis in a tamoxifen-treated, postmenopausal breast cancer patient showed similarity to tamoxifen-induced epithelial differentiation of the endometrium ( Ismail and Maulik, 1997 ).…”

Section: Tumor-like Diseasesmentioning

confidence: 98%

“…A histopathologic analysis of endometriosis in a tamoxifen-treated, postmenopausal breast cancer patient showed similarity to tamoxifen-induced epithelial differentiation of the endometrium ( Ismail and Maulik, 1997 ). The development of endometriosis has been frequently reported in postmenopausal patients taking tamoxifen ( Hajjar et al 1993 ; Cohen et al 1994b ; Ismail and Maulik, 1997 ). Several cases of endometriosis in the ovary have also been described in premenopausal women during tamoxifen administration ( Ford et al 1988 ; Cano et al 1989 ; Morgan et al 1994 ).…”

Section: Tumor-like Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Tumorigenic Effects of Tamoxifen on the Female Genital Tract

Nasu

Takai

Nishida

et al. 2008

Clinical medicine. Pathology

View full text Add to dashboard Cite

Tamoxifen is widely used for endocrine treatment and breast cancer prevention. It acts as both an estrogen antagonist in breast tissue and an estrogen agonist in the female lower genital tract. Tamoxifen causes severe gynecologic side effects, such as endometrial cancer. This review focuses on the effects of prolonged tamoxifen treatment on the human female genital tract and considers its tumorigenicity in the gynecologic organs through clinical data analysis. Tamoxifen is associated with an increased incidence of benign endometrial lesions such as polyps and hyperplasia and a two-to four-fold increased risk of endometrial cancer in postmenopausal patients. Moreover, the incidence of functional ovarian cysts is signifi cantly high in premenopausal tamoxifen users. To prevent tamoxifen from having severe side effects in gynecologic organs, frequent gynecological examination should be performed for both premenopausal and postmenopausal patients with breast cancer who are treated with this drug.

show abstract

Section: Endometriosismentioning

confidence: 89%

Section: Endometriosismentioning

confidence: 94%

Section: Tumor-like Diseasesmentioning

confidence: 98%

Section: Tumor-like Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Tumorigenic Effects of Tamoxifen on the Female Genital Tract

Nasu

Takai

Nishida

et al. 2008

Clinical medicine. Pathology

View full text Add to dashboard Cite

show abstract

“…The first case with endometriosis related to TMX, a 50-year-old woman who has had a 2-year adjuvant TMX treatment due to breast carcinoma and had extensive pelvic endometriosis necessitated surgery, has been reported in 1993 [22]. Next year, a 57-year-old woman with operated-breast carcinoma and treated with chemotherapy and adjuvant TMX has been reported to have endometriosis and endometrioid carcinoma of the gastrointestinal [23].…”

Section: Tamoxifen and Postmenopausal Endometriosismentioning

confidence: 99%

Endometriosis after Menopause

İnceboz¹

2015

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Endometriosis is a common but an enigmatic disease in which endometrial glands and stroma are found outside the uterus. Worldwide, 80 million women are affected by the disease. It has generally been accepted as a problem of reproductive ages and affects 6-10% of those women. It is more common in women with infertility. Moreover, since it is an estrogen dependent problem, it is generally believed that endometriosis connotes 'active ovarian function' and is 'healed' after the menopause. However, there are reports on endometriosis beyond the reproductive ages. In this article, endometriosis after the menopause will be discussed.

show abstract